IHC, or ImmunoHistoChemistry, is a special staining process performed on fresh or frozen breast cancer tissue removed during biopsy. IHC is used to show whether or not the cancer cells have HER2 receptors and/or hormone receptors on their surface. This information plays a critical role in treatment planning.
IHC is the most commonly used test to see if a tumor has too much of the HER2 receptor protein on the surface of the cancer cells. With too many receptors, the cells receive too many growth signals.
The IHC test gives a score of 0 to 3+ that indicates the amount of HER2 receptor protein on the cells in a sample of breast cancer tissue. If the tissue scores 0 to 1+, it’s called “HER2 negative.” If it scores 2+ or 3+, it’s called “HER2 positive.” If the results are between 1 and 2, they're considered borderline.
Research has shown that some HER2 status test results may be wrong. This is probably because different labs have different rules for classifying positive and negative HER2 status. Each pathologist also may use slightly different criteria to decide whether the results are positive or negative. In most cases, this happens when the test results are borderline -- meaning they aren't strongly HER2-positive or HER2-negative.
In other cases, tissue from one area of a breast cancer can test HER2-positive and tissue from a different area of the cancer can test HER2-negative.
Inaccurate HER2 test results may cause women diagnosed with breast cancer to not get the best care possible. If all or part of a breast cancer is HER2-positive but test results classify it as HER2-negative, doctors aren't likely to recommend Herceptin or Tykerb treatment -- even though the woman could potentially benefit from those medicines. If a breast cancer is HER2-negative but test results classify it as HER2-positive, doctors may recommend Herceptin or Tykerb treatment -- even though the woman is unlikely to get any benefits and is exposed to the medicines' risks.
If your IHC HER2 test results are negative or borderline, you may want to ask your doctor about getting the FISH test, which uses different technology to measure HER2 status. If the FISH test results are borderline, you might want to ask your doctor if more than one pathologist reviewed the results. If the HER2 test results weren't reviewed by more than one pathologist, you may want to ask if the results can be reviewed again.
The IHC test results are most reliable for fresh or frozen tissue samples. IHC tends to be an unreliable way to test tissue that's preserved in wax or other chemicals.
People with HER2-positive scores tend to respond favorably to Herceptin. The medication is not considered effective for tumors with IHC scores of 0 or 1+.
It's important to note that results on the IHC test may vary from lab to lab and that some labs are more experienced with testing for HER2 than others. Talk to your doctor about the possibility of also getting a FISH test, which uses another technology for measuring HER2 — especially if you have a 1+ or 2+ result from IHC.
The IHC test results are most reliable for fresh or frozen tissue samples. IHC tends to be an unreliable way to test tissue that's preserved in wax or other chemicals.
Most testing labs use the IHC staining process to make any hormone receptors show up on the cells in sample of breast cancer tissue. If hormone receptors are present, this means that the cancer cells’ growth is fueled by the female hormones estrogen and/or progesterone. The cancer is likely to respond to hormone therapies such as tamoxifen and aromatase inhibitors, which block the action of estrogen or lower estrogen levels in the body.
Not all labs use the same method for analyzing the results of the test, and they do not have to report the results in exactly the same way. So you may see any of the following when you get your results back:
Keep in mind that a test should be done for both estrogen receptors and progesterone receptors.
If your result is reported as just the word “positive” or “negative,” ask your doctor for a more definite percentage, rating, or other number. Different labs have different cutoff points for calling the cancer either hormone-receptor-positive or hormone-receptor-negative. For example, if less than 10% of your cells stain positive (fewer than 1 in 10), one lab might call this a negative result. Another lab might consider this positive, even though it is a low test result. Research studies have shown that any positive result, no matter how low, suggests that hormone therapy could be of benefit. A score of “0” is needed to completely rule out hormone therapy as an option.
Sometimes, a report will come back from the laboratory saying that the hormone status is “unknown.” This can mean one of several things:
If there are no hormone receptors present, or they cannot be measured or seen, the cancer is called hormone-receptor-negative.
Talk with your doctor to make sure that your test is done by a laboratory with a great deal of experience in IHC testing for hormone receptors. The more tests the lab does, the more accurate your results are likely to be. If you receive a negative test result, ask for a complete explanation as to why the cancer is considered hormone-receptor-negative. You also might ask to have a sample of the tumor tested again.
Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.
Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003
©2012 Breastcancer.org - All rights reserved.